Development, Commercialization and Supply Agreement - Additional Information (Detail) - USD ($)	1 Months Ended										3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Feb. 28, 2023	Jan. 31, 2023	Jan. 31, 2022	Feb. 29, 2020	Jan. 31, 2020	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2016	Feb. 28, 2015	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2018	Jul. 31, 2023	Dec. 31, 2021
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments													$ 14,990,000	$ 701,000
Licenses revenue											$ 80,167,000	$ 94,440,000	166,142,000	189,070,000
Deferred revenue	$ 5,356,000										5,356,000	16,008,000	5,356,000	16,008,000	$ 15,346,000			$ 16,709,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue											65,187,000	93,796,000	149,841,000	187,782,000
Marine
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments													(3,900,000)
Mochida Pharmaceutical Co., Ltd. | In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment			$ 1,000,000	$ 1,000,000
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense
License And Collaboration Agreements [Line Items]
Upfront payment																$ 2,700,000
Edding
License And Collaboration Agreements [Line Items]
Additional license revenues	5,000,000										5,000,000		5,000,000
Revenue recognized related to upfront and milestone payments													(5,000,000)
Edding | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received										$ 15,000,000
Amounts to be received upon achievement of the regulatory milestone events	33,000,000										33,000,000		33,000,000
Milestone payments received													6,000,000
Sales-based milestone event payment	120,000,000										120,000,000		120,000,000
Revenue recognized related to upfront and milestone payments													9,400,000	300,000
Deferred revenue	4,900,000										4,900,000		4,900,000		9,300,000
Edding | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue													17,100,000		7,700,000
Edding | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue													0	0
Edding | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone	148,000,000										148,000,000		148,000,000
Amounts to be received upon achievement of the regulatory milestone events	15,000,000										15,000,000		15,000,000
Sales-based milestone event payment	50,000,000										50,000,000		50,000,000
Edding | Out-licenses | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events	2,000,000										2,000,000		2,000,000
Sales-based milestone event payment	5,000,000										5,000,000		5,000,000
Edding | Out-licenses | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received									$ 1,000,000
Edding | Out-licenses | Marine
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone	3,900,000										3,900,000		3,900,000
Additional license revenues	5,000,000										5,000,000		5,000,000
Remaining performance period amount	1,100,000										1,100,000		$ 1,100,000
Reduction in net loss											5,000,000
Edding | Out-licenses | Marine | VASCEPA
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received	5,000,000										5,000,000
Edding | Out-licenses | Marine | Maximum
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment													3 years
Edding | Out-licenses | Marine | Minimum
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment													11 years
Biologix FZCo
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment													8 years
Biologix FZCo | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received													$ 5,300,000
Revenue recognition period of non-refundable up-front payment									10 years
Reduction in net loss											5,300,000
Biologix FZCo | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue											0	0	300,000	0
HLS
License And Collaboration Agreements [Line Items]
Additional license revenues	$ 5,300,000										5,300,000		5,300,000
Revenue recognized related to upfront and milestone payments													(5,300,000)
HLS | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received								$ 5,000,000
Non-refundable milestone payment received					$ 2,500,000	$ 3,800,000	$ 2,500,000
Revenue recognized related to upfront and milestone payments													5,600,000	300,000
Deferred revenue															5,600,000
Non-refundable up-front received period								6 months
Non-refundable milestone payment received								$ 3,800,000
HLS | Out-licenses | Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received								2,500,000
HLS | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue													13,800,000		$ 8,200,000
HLS | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue											$ 0	$ 2,300,000	1,600,000	$ 2,300,000
HLS | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone								50,000,000
HLS | Out-licenses | Achievement of REDUCE-IT Trial
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received								$ 2,500,000
CSL Seqirus | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received		$ 500,000
Licenses revenue													$ 500,000
Upfront payment receivable		500,000
Event-related milestone payments receivable		8,000,000
Additional product-related milestone payments receivable		$ 4,000,000
Lotus Pharmaceuticals | Subsequent Event | VAZKEPA
License And Collaboration Agreements [Line Items]
Upfront payment receivable																	$ 300,000